• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[伴有骨转移的乳腺癌患者尿羟脯氨酸的变化行为]

[Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].

作者信息

Polico C, Nascimben O, Maccari F, Fazzin G

出版信息

Quad Sclavo Diagn. 1978 Dec;14(4):486-93.

PMID:757622
Abstract

Serial estimations of the hydroxyproline (OHP) excretion during chemotherapy were performed in 24 women bearing advanced breast carcinoma with skeletal metastases. There was a significant correlation between sensitivity of the metastases to treatment and OHP content of urine. Many factors, including age of patients, type, number and extent of metastases, don't influence OHP excretion. The estimation of the urinary OHP levels, with the changes after antiblastic treatment, can be useful in prognostic evaluation of the metastatic breast cancer.

摘要

对24例患有晚期乳腺癌伴骨转移的女性患者在化疗期间进行了羟脯氨酸(OHP)排泄的系列评估。转移灶对治疗的敏感性与尿液中的OHP含量之间存在显著相关性。许多因素,包括患者年龄、转移灶的类型、数量和范围,均不影响OHP的排泄。通过评估尿液中OHP水平以及抗胚细胞治疗后的变化,有助于对转移性乳腺癌进行预后评估。

相似文献

1
[Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].[伴有骨转移的乳腺癌患者尿羟脯氨酸的变化行为]
Quad Sclavo Diagn. 1978 Dec;14(4):486-93.
2
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].[晚期乳腺癌患者尿羟脯氨酸水平及大剂量醋酸甲羟孕酮(MAP)治疗反应]
Minerva Med. 1980 Sep 1;71(31):2215-9.
3
[Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].[乳腺癌骨转移患者垂体切除术前、后的尿羟脯氨酸排泄情况]
Ugeskr Laeger. 1968 Oct 17;130(42):1766-71.
4
[Hydroxyproline in the diagnosis of bone metastases in breast cancer].[羟脯氨酸在乳腺癌骨转移诊断中的应用]
Schweiz Med Wochenschr. 1977 Jul 16;107(28):984-6.
5
A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.比较骨相关生物标志物和CA27.29以评估骨转移性乳腺癌的治疗反应。
Anticancer Res. 2000 Nov-Dec;20(6D):5099-105.
6
Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.使用TPS和CA 15-3检测来监测转移性乳腺癌患者的化疗情况。
Anticancer Res. 2000 Nov-Dec;20(6D):5089-93.
7
[Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].[血清Ca 15-3抗原升高:乳腺癌远处转移的早期指标。733例回顾性分析]
Przegl Lek. 2001;58(6):498-503.
8
Biochemical picture of bone metabolism in breast cancer patients with bone metastases.伴有骨转移的乳腺癌患者骨代谢的生化情况
Anticancer Res. 1995 Nov-Dec;15(6B):2871-5.
9
Hydroxyproline and zinc excretion in patients with neoplastic breast disease.患有乳腺肿瘤疾病患者的羟脯氨酸和锌排泄情况。
Int Surg. 1981 Jul-Sep;66(3):233-6.
10
Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Arch Intern Med. 1981 Oct;141(11):1471-3.